SEC Form 4 · accession 0001104659-17-052470
Cardiff Oncology, Inc. · CRDF
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William J Welch
Officer — CEO · Director
Period of report
Aug 15, 2017
Accepted (ET)
Aug 17, 2017 · 4:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001213037
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 15, 2017 | A | 745,392 | — | A | 745,392 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Mr. Welch was granted a stock award of 745,392 shares of common stock pursuant to the Trovagene, Inc. 2014 Equity Incentive Plan which vested upon date of grant.